- Conditions
- Breast Cancer
- Interventions
- Anastrozole
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–101
of 101
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anovulation
- Interventions
- Anastrozole 1 mg, Anastrozole 5 mg, Anastrozole 10 mg, Clomiphene Citrate 50 mg, Clomiphene Citrate 100 mg
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Vandetanib, Anastrozole
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor, Selective estrogen receptor modulator (SERM)
- Biological · Drug
- Lead sponsor
- Finn, Olivera, PhD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Palbociclib, Aromatase Inhibitor
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 10
- States / cities
- San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 5 more